Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...

Understand the cash flow statement for Replimune Group, Inc. (REPL), learn where the money comes from and how the company spends it.

Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In October, the FDA accepted the resubmission of the biologics license application ...

Dividend Yield 5 Year Avg. Replimune has a price-to-earnings (P/E) ratio of -2.06 (TTM). This compares to an industry average of -10.55. What is Replimune’s price-to-book (P/B) ratio? Replimune’s ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Find out the direct holders, institutional holders and mutual fund holders for Replimune Group, Inc. (REPL).

The client provides an easy way to send Ajax requests to the server using GET, POST, and PUT functions. It also provides a simple way using ajax-request. All requests ...

The explicit [query filters] and [results] argument lists declare what travels across the wire. The macro validates at compile-time that you're not accidentally forgetting variables.